Althea Technologies Acquires Altus Pharmaceuticals' Assets and IP Portfolio
Althea Technologies, Inc. (San Diego, CA), a provider of services for biopharmaceutical development and manufacturing will acquire the assets and IP portfolio of Altus Pharmaceuticals (Cambridge, MA).
Althea Technologies, Inc. (San Diego, CA), a provider of services for biopharmaceutical development and manufacturing will acquire the assets and IP portfolio of Altus Pharmaceuticals (Cambridge, MA). The IP portfolio includes, among other things, Altus’ Cross Linked enzyme crystal and controlled release injectable technologies. Applications of this protein crystal technology range from therapeutics to protein purification and catalysis. The controlled release injectable technology involves protein crystallization and complexation using customized manufacturing equipment installed at Althea.
Additionally, the assets encompass a portfolio of product candidates based on these technologies that includes a seven day controlled release growth hormone injectable that has completed a Phase 2 clinical trial. Althea was the manufacturer of clinical supplies for these product candidates and plans to enter into licensing discussions for them.
AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline
August 2nd 2024With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.
